Hikma PharmaceuticalsHKMPF 82 Days Inventory is 206.90 as of Dec. 2025, which is 3% above its 10-year median of 200.77. GuruFocus rates HKMPF with a GF Score™ of 82/100 and a GF Value™ of $28.50 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 918 Drug Manufacturers companies, Hikma Pharmaceuticals ranks worse than 66.34% on this metric.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Hikma Pharmaceuticals's Inventory Turnover for the
six
months ended in Dec. 2025 was 0.88.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Hikma Pharmaceuticals's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.65.
Hikma Pharmaceuticals (OTCPK:HKMPF) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Hikma Pharmaceuticals's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Hikma Pharmaceuticals's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Hikma Pharmaceuticals Days Inventory Related Terms
Hikma Pharmaceuticals Days Inventory Historical Data
* Premium members only.
The historical data trend for Hikma Pharmaceuticals's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKMPF vs ZTS, UTHR, VTRS: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikma Pharmaceuticals Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where Hikma Pharmaceuticals's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hikma Pharmaceuticals (HKMPF) has a Days Inventory of 206.90 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Hikma Pharmaceuticals and its competitors. This is near median its historical median of 200.77. Over the past decade, Hikma Pharmaceuticals' Days Inventory has ranged from 126.52 to 214.44. According to the industry distribution chart, Hikma Pharmaceuticals ranks #609 out of 918 companies in the Drug Manufacturers industry, placing it in the top 66.3%.
Is Hikma Pharmaceuticals' Days Inventory too high?
Hikma Pharmaceuticals' current Days Inventory of 206.90 is near median its 10-year median of 200.77. Over the past 10 years, this metric has ranged from a low of 126.52 to a high of 214.44. The Drug Manufacturers industry median Days Inventory is 164.43. Hikma Pharmaceuticals' value of 206.90 is 25.8% above this industry median. Based on the distribution chart, Hikma Pharmaceuticals ranks #609 out of 918 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Hikma Pharmaceuticals has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hikma Pharmaceuticals ranks #609 out of 918 companies for Days Inventory. This places Hikma Pharmaceuticals in the lower half of its industry. The industry median Days Inventory is 164.43. Hikma Pharmaceuticals' value of 206.90 is 25.8% above this benchmark. Historically, Hikma Pharmaceuticals' own Days Inventory has ranged from 126.52 to 214.44 over the past decade. While the company's 10-year median is 200.77 vs. the industry median of 164.43, Hikma Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.43, based on 918 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hikma Pharmaceuticals's current Days Inventory of 206.90 is 25.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Hikma Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hikma Pharmaceuticals's current Days Inventory is 206.90, which is near median its own 10-year median of 200.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPF) is currently considered Modestly Undervalued. The stock's GF Value™ is $28.50, compared to a current price of $20.12 — trading 29.4% below its estimated fair value. The current Days Inventory is 206.90, which is near median its 10-year median of 200.77 and 25.8% above the Drug Manufacturers industry median of 164.43. Hikma Pharmaceuticals' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPF), the current Days Inventory is 206.90 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hikma Pharmaceuticals (HKMPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued.
The current stock price of $20.12 is trading 29.4% below its estimated GF Value™ of $28.50.
GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for HKMPF:
Days Inventory: 206.90 (near median its 10-year median of 200.77)
GF Value™: $28.50 vs. price of $20.12 (29.4% below fair value)
Industry Position: 25.8% above the Drug Manufacturers median (#609 of 918)
No single metric tells the full story. See the HKMPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
82GF Score
Get the complete analysis for HKMPF
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKMPF has been successfully added to your 
